Access Consortium

The Access consortium is a medium-sized coalition of regulatory authorities from Australia, Canada, Singapore, Switzerland and the UK that work together to promote greater regulatory collaboration and alignment of regulatory requirements.

The Access consortium is a medium-sized coalition of regulatory authorities from Australia, Canada, Singapore, Switzerland and the UK that work together to promote greater regulatory collaboration and alignment of regulatory requirements.

The Access Consortium is a collaborative initiative between five Health Authorities: Australia’s Therapeutic Goods Administration (TGA), Health Canada (HC), Singapore’s Health Sciences Authority (HSA), the Swiss Agency for Therapeutic Products (Swissmedic) and the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK. It intends to build synergies and maximize international cooperation to ensure patients’ timely access to safe therapeutic products in the member countries.

The Access Consortium consist of different working groups:

  • New Active Substances working group
  • Generic Medicines working group
  • COVID-19 vaccines and therapeutics working group
  • Biosimilars working group
  • Complementary Health Products working group
  • Information Technology working group

 

Asphalion can provide support throughout the whole process in a variety of activities, discover how!

Download here:

Share

LinkedIn
Twitter
WhatsApp
Email
Access consortium
November 21, 2022
| By Asphalion

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting